AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific adverse events
Number of subjects: 37
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM flare
Number of subjects: 37
Study 27914971 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 37
Study 27915408 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib 0.4 mg/kg
Number of subjects: 10
Study 27915408 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib 0.8 mg/kg
Number of subjects: 10
Study 27915408 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (both doses)
Number of subjects: 10
Study 27915457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using the RASP list and medication review
Number of subjects: 172
Study 27915457 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual geriatric care)
Number of subjects: 172
Study 27916234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom motor execution using machine learning, augmented and virtual reality, and serious gaming (12 sessions)
Number of subjects: 14
Study 27916627 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 0
Study 27916627 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27917531 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster
Number of subjects: 412
Study 27917531 — intervention group
Group type: EXPERIMENTAL
Intervention: Postherpetic neuralgia
Number of subjects: 412
Study 27917531 — intervention group
Group type: EXPERIMENTAL
Intervention: Other complications
Number of subjects: 412
Study 27917531 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 412
Study 27917531 — intervention group
Group type: COMPARATOR
Intervention: Age 70-74 years
Number of subjects: 412
Study 27917531 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 412
Study 27917531 — intervention group
Group type: COMPARATOR
Intervention: Severe herpes zoster pain at first consultation
Number of subjects: 412
Study 27917531 — intervention group
Group type: COMPARATOR
Intervention: Rash on upper arms
Number of subjects: 412
Study 27917600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B (e antigen positive)
Number of subjects: 1390
Study 27917600 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B (e antigen negative)
Number of subjects: 1390
Study 27917600 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive carriers
Number of subjects: 1390
Study 27917600 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminant cases
Number of subjects: 1390
Study 27917600 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall categorization of chronic hepatitis B
Number of subjects: 1390
Study 27918827 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma subjects
Number of subjects: 100
Study 27918827 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100
Study 27918881 — intervention group
Group type: EXPERIMENTAL
Intervention: QUIT4EVER (mobile contingency management smoking cessation counseling and medications + Stay Quit Coach)
Number of subjects: 11
Study 27918881 — intervention group
Group type: COMPARATOR
Intervention: Contact control condition (identical to QUIT4EVER but without Stay Quit Coach)
Number of subjects: 11
Study 27919055 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 2756
Study 27919055 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy responders
Number of subjects: 2756
Study 27919055 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and comorbidities
Number of subjects: 2756
Study 27919055 — intervention group
Group type: EXPERIMENTAL
Intervention: High NIHSS score
Number of subjects: 2756
Study 27919259 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with Reverdin-Isham and Akin percutaneous osteotomy
Number of subjects: 80
Study 27919438 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 0
Study 27919438 — intervention group
Group type: COMPARATOR
Intervention: Non-obese subjects (control)
Number of subjects: 0
Study 27919491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 0
Study 27919491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0
Study 27919491 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study 27919491 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study 27919491 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability worsening
Number of subjects: 0
Study 27919506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 25
Study 27919862 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD (MLC601) for 6 months in addition to standard care
Number of subjects: 0
Study 27919862 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD (MLC601)
Number of subjects: 0
Study 27919899 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg once daily (QD)
Number of subjects: 22
Study 27919899 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir 600 mg twice daily (BID)
Number of subjects: 22
Study 27919899 — intervention group
Group type: COMPARATOR
Intervention: Three-direct-acting antiviral (3D) regimen with ribavirin (RBV)
Number of subjects: 22
Study 27920519 — intervention group
Group type: EXPERIMENTAL
Intervention: telemonitoring plus education
Number of subjects: 119
Study 27920519 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 119
Study 27920566 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily, Deleobuvir 600 mg twice daily, Ribavirin (weight-based) for 16 weeks (Arm 1)
Number of subjects: 208
Study 27920566 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily, Deleobuvir 600 mg twice daily, Ribavirin (weight-based) for 24 weeks (Arm 2)
Number of subjects: 208
Study 27920566 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily, Deleobuvir 600 mg twice daily, Ribavirin (weight-based) for 24 weeks (Arm 3)
Number of subjects: 208
Study 27921221 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every 4 weeks
Number of subjects: 97
Study 27921340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (speech exposure session)
Number of subjects: 24
Study 27921340 — intervention group
Group type: EXPERIMENTAL
Intervention: Better extinction learning (less negative stimulus ratings)
Number of subjects: 24
Study 27922747 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) score
Number of subjects: 1040
Study 27923043 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily until progression
Number of subjects: 26
Study 27923043 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily and intravenous vinorelbine 25 mg/m2 weekly after progression
Number of subjects: 26
Study 27923043 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-naïve patients with somatic activation of PI3K/Akt signalling
Number of subjects: 26
Study 27923043 — intervention group
Group type: COMPARATOR
Intervention: Afatinib combined with vinorelbine
Number of subjects: 26
Study 27923359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (doses ranged from 12.5 to 150 mg/day, mostly 25 and 50 mg/day)
Number of subjects: 122
Study 27923359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 122
Study 27923461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin strut biodegradable-polymer (BP) sirolimus-eluting stents (SES)
Number of subjects: 2119
Study 27923461 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer (DP) everolimus-eluting stents (EES)
Number of subjects: 2119
Study 27923461 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex patients
Number of subjects: 2119
Study 27923779 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary model to guide employment outcomes among PLWSCI
Number of subjects: 0
Study 27923814 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 0
Study 27923814 — intervention group
Group type: COMPARATOR
Intervention: Sera from acute KD patients
Number of subjects: 0
Study 27925796 — intervention group
Group type: COMPARATOR
Intervention: Blood analysis and gene expression profiling
Number of subjects: 610
Study 27925796 — intervention group
Group type: COMPARATOR
Intervention: Severe asthma subgroup
Number of subjects: 610
Study 27925796 — intervention group
Group type: COMPARATOR
Intervention: Pathway analysis
Number of subjects: 610
Study 27925796 — intervention group
Group type: COMPARATOR
Intervention: Cluster analysis of DEGs
Number of subjects: 610
Study 27926445 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of performance after good performance plus a monetary reward
Number of subjects: 0
Study 27926445 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of performance after a random selection of trials
Number of subjects: 0
Study 27926445 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of performance after good performance
Number of subjects: 0
Study 27926649 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting excessive gestational weight gain
Number of subjects: 230
Study 27926649 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting excessive gestational weight gain (adjusted for previous weight gain and sociodemographic characteristics)
Number of subjects: 230
Study 27926904 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support for weight loss
Number of subjects: 0
Study 27926979 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs), median duration of 27.5 months (range 0-77 months)
Number of subjects: 1696
Study 27926979 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 1696
Study 27927586 — intervention group
Group type: EXPERIMENTAL
Intervention: RBAC500 (rituximab 375 mg/m2, bendamustine, low-dose cytarabine)
Number of subjects: 57
Study 27927586 — intervention group
Group type: EXPERIMENTAL
Intervention: RBAC500
Number of subjects: 57
Study 27927609 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)
Number of subjects: 300
Study 27927609 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated population pharmacokinetic (PopPK) models
Number of subjects: 300
Study 27927609 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized estimates of PK parameters
Number of subjects: 300
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake of 200-249 μg/d for children aged 7-10 y
Number of subjects: 2089
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake of 250-299 μg/d for children aged 11-14 y
Number of subjects: 2089
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake ≥150 μg/d
Number of subjects: 2089
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake ≥250 μg/d for children aged 7-10 y
Number of subjects: 2089
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake ≥300 μg/d for children aged 11-14 y
Number of subjects: 2089
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake of 150-249 μg/d for children aged 7-10 y
Number of subjects: 2089
Study 27927635 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine intake of 150-299 μg/d for children aged 11-14 y
Number of subjects: 2089
Study 27927677 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA) with AngioVue
Number of subjects: 50
Study 27927677 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA) with AngioPlex
Number of subjects: 50
Study 27927677 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography (FA)
Number of subjects: 50
Study 27927700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac α intervention
Number of subjects: 0
Study 27927766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebastinib (DCC-2036) administered at doses from 57 mg to 1200 mg daily (powder-in-capsule) and 100 mg to 400 mg daily (tablet preparations). Maximum tolerated dose was 150 mg tablets administered twice daily.
Number of subjects: 57
Study 27928583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic hepatitis (HH)
Number of subjects: 172
Study 27928583 — intervention group
Group type: COMPARATOR
Intervention: No hypoxic hepatitis (HH)
Number of subjects: 172
Study 27928583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate-aminotransferase (ASAT)
Number of subjects: 172
Study 27928583 — intervention group
Group type: EXPERIMENTAL
Intervention: New biomarkers (argininosuccinate synthase 1 and sulfotransferase isoform SULT2A1)
Number of subjects: 172
Study 27928641 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dental assessment
Number of subjects: 2294
Study 27928641 — intervention group
Group type: COMPARATOR
Intervention: None to mild plaque, calculus, gingivitis, or periodontal disease
Number of subjects: 2294
Study 27928641 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dental conditions (poor oral hygiene)
Number of subjects: 2294
Study 27928738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg
Number of subjects: 16
Study 27928738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 40 mg
Number of subjects: 16
Study 27929312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session adolescent program with an additional parent session (BI-AP)
Number of subjects: 259
Study 27929312 — intervention group
Group type: COMPARATOR
Intervention: 2-session adolescent-only program (BI-A)
Number of subjects: 259
Study 27930357 — intervention group
Group type: EXPERIMENTAL
Intervention: High adenosine dose (200 μg/kg per minute)
Number of subjects: 30
Study 27930357 — intervention group
Group type: COMPARATOR
Intervention: Standard adenosine dose (140 μg/kg per minute)
Number of subjects: 30
Study 27930660 — intervention group
Group type: EXPERIMENTAL
Intervention: P. vivax infection
Number of subjects: 0
Study 27930660 — intervention group
Group type: COMPARATOR
Intervention: P. falciparum infection
Number of subjects: 0
Study 27931196 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attentional bias training
Number of subjects: 32
Study 27931196 — intervention group
Group type: COMPARATOR
Intervention: Yoked-control group
Number of subjects: 32
Study 27931243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 400 mg QD
Number of subjects: 74
Study 27931243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 100 to 600 mg QD
Number of subjects: 74
Study 27931243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib 500 mg QD
Number of subjects: 74
Study 27931243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 74
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET) at 1 month and 12 months
Number of subjects: 100
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment
Number of subjects: 100
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea assessment
Number of subjects: 100
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD) testing
Number of subjects: 100
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual clot burden measurement (perfusion scan, CT pulmonary angiography)
Number of subjects: 100
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac function assessment (echocardiography)
Number of subjects: 100
Study 27932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFTs)
Number of subjects: 100
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.2 mg/kg every 3 weeks
Number of subjects: 82
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.4 mg/kg every 3 weeks
Number of subjects: 82
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.3 mg/kg every 6 weeks
Number of subjects: 82
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.4 mg/kg every 6 weeks
Number of subjects: 82
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.8 mg/kg every 3 weeks
Number of subjects: 82
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (various doses)
Number of subjects: 82
Study 27932068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (high DLL3 expression)
Number of subjects: 82
Study 27932427 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (implanted for <6 weeks)
Number of subjects: 16
Study 27932427 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (implanted for ≥ 6 weeks)
Number of subjects: 16
Study 27932427 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (chronic retrieval cohort)
Number of subjects: 16
Study 27932427 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker retrieval procedure
Number of subjects: 16
Study 27932562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerenkov luminescence imaging (CLI) for intraoperative assessment of tumor resection margins
Number of subjects: 0
Study 27932562 — intervention group
Group type: COMPARATOR
Intervention: Standard methods for assessing resection margins (not specified)
Number of subjects: 0
Study 27932629 — intervention group
Group type: EXPERIMENTAL
Intervention: London Chest Activities of Daily Living Scale
Number of subjects: 88
Study 27932629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire
Number of subjects: 88
Study 27932629 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care Outcome Scale
Number of subjects: 88
Study 27932629 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care Outcome Scale-symptoms
Number of subjects: 88
Study 27932629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 88
Study 27932629 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness measured on a numerical rating scale
Number of subjects: 88
Study 27932687 — intervention group
Group type: EXPERIMENTAL
Intervention: High diabetes distress
Number of subjects: 268
Study 27932687 — intervention group
Group type: EXPERIMENTAL
Intervention: High diabetes distress (<18 years)
Number of subjects: 268
Study 27932687 — intervention group
Group type: COMPARATOR
Intervention: Low or moderate diabetes distress
Number of subjects: 268
Study 27933186 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI (GI≥65) with high carbohydrate (58% kcal)
Number of subjects: 163
Study 27933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI (GI≤45) with low carbohydrate (40% kcal)
Number of subjects: 163
Study 27933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI with high carbohydrate
Number of subjects: 163
Study 27933186 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI with low carbohydrate
Number of subjects: 163
Study 27933186 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing carbohydrate content (regardless of GI)
Number of subjects: 163
Study 27933199 — intervention group
Group type: EXPERIMENTAL
Intervention: RCI 40 U daily
Number of subjects: 38
Study 27933199 — intervention group
Group type: EXPERIMENTAL
Intervention: RCI 80 U every other day
Number of subjects: 38
Study 27933199 — intervention group
Group type: COMPARATOR
Intervention: Combined placebo
Number of subjects: 38
Study 27933199 — intervention group
Group type: EXPERIMENTAL
Intervention: RCI treatment
Number of subjects: 38
Study 27933201 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 356
Study 27933201 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite NASH
Number of subjects: 356
Study 27933201 — intervention group
Group type: COMPARATOR
Intervention: No MetS
Number of subjects: 356
Study 27933289 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age at immigration and increased duration of stay in the US
Number of subjects: 238
Study 27933289 — intervention group
Group type: EXPERIMENTAL
Intervention: Family reunification
Number of subjects: 238
Study 27933289 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy assimilation behavior (higher prevalence of smoking, alcohol consumption, or sedentary activity)
Number of subjects: 238
Study 27933679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation for 2 weeks
Number of subjects: 60
Study 27935524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low urinary potassium excretion (UKV <55 mmol/24 h for women; <65 mmol/24 h for men)
Number of subjects: 705
Study 27935524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean urinary potassium excretion (UKV) in RTRs
Number of subjects: 705
Study 27935524 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 705
Study 27935737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 30 minutes, three times weekly for 4 weeks
Number of subjects: 53
Study 27935737 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 53
Study 27935867 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 (MK-8628)
Number of subjects: 3
Study 27935867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OTX015 and everolimus
Number of subjects: 3
Study 27935867 — intervention group
Group type: COMPARATOR
Intervention: Everolimus alone
Number of subjects: 3
Study 27935867 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX015 as single agent
Number of subjects: 3
Study 27935867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with everolimus
Number of subjects: 3
Study 27936016 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-Type HRV-16 Challenge Virus
Number of subjects: 0
Study 27936016 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 1 TCID50
Number of subjects: 0
Study 27936016 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 10 TCID50
Number of subjects: 0